|
|
Volumn 167 Suppl 3, Issue , 2012, Pages 12-20
|
|
Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
BIOLOGICAL PRODUCT;
DERMATOLOGICAL AGENT;
IMMUNOGLOBULIN G;
INFLIXIMAB;
MONOCLONAL ANTIBODY;
TNFR FC FUSION PROTEIN;
TNFR-FC FUSION PROTEIN;
TUMOR NECROSIS FACTOR ALPHA;
TUMOR NECROSIS FACTOR RECEPTOR;
USTEKINUMAB;
COMPARATIVE STUDY;
DRUG ANTAGONISM;
DRUG SUBSTITUTION;
HUMAN;
PRACTICE GUIDELINE;
PSORIASIS;
REVIEW;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, MONOCLONAL, HUMANIZED;
BIOLOGICAL AGENTS;
DERMATOLOGIC AGENTS;
DRUG SUBSTITUTION;
HUMANS;
IMMUNOGLOBULIN G;
PRACTICE GUIDELINES AS TOPIC;
PSORIASIS;
RECEPTORS, TUMOR NECROSIS FACTOR;
TREATMENT OUTCOME;
TUMOR NECROSIS FACTOR-ALPHA;
MLCS;
MLOWN;
|
|
EID: 84873427294
PISSN: None
EISSN: 13652133
Source Type: Journal
DOI: 10.1111/j.1365-2133.2012.11209.x Document Type: Review |
|
Times cited : (47)
|
|
References (0)
|
